HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

Published:2024-02-01 Issue:7 Volume:134 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Li Zheqi^ORCID,Metzger Filho Otto,Viale Giuseppe,dell’Orto Patrizia,Russo Leila,Goyette Marie-Anne^ORCID,Kamat Avni,Yardley Denise A.,Gupta Abramson Vandana,Arteaga Carlos L.,Spring Laura M.,Chiotti Kami^ORCID,Halsey Carol,Waks Adrienne G.,King Tari A.,Lester Susan C.,Bellon Jennifer R.,Winer Eric P.^ORCID,Spellman Paul T.^ORCID,Krop Ian E.,Polyak Kornelia^ORCID

Funder

National Cancer Institute

Publisher

American Society for Clinical Investigation

Link

https://www.jci.org/articles/view/176454/files/pdf

Reference40 articles.

1. Cancer statistics, 2023

2. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

3. HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer

4. Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

5. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP